SCA Global Launches Website The inaugural meeting of the SCA Global initiative was held at NAF’s Annual Ataxia Conference in April of 2018. Researchers from around the world created a global collaboration in clinical research efforts for Spinocerebellar Ataxias (SCA). SCA Global was created to address the obstacles that clinical Read More…

Thanks NAF Donors for Helping Make It Possible In 2015, Miao Zhang, Ph.D. was early in his career on the Ataxia research scene, but he had a strong desire to look for answers. He applied for a Young Investigator Grant from the National Ataxia Foundation to help get his project Read More…

Join the 2017 Research Drive to Help #CureAtaxia The Annual Ataxia Research Drive began on October 15 with the challenge to raise $400,000 by December 15 to fund the finest Ataxia research. There were 84 research applications submitted to the National Ataxia Foundation for consideration. They are currently being peer-reviewed Read More…

BIOHAVEN OPTIMISTIC FOR NEXT PHASE OF TRIAL DESPITE DISAPPOINTING TOPLINE DATA As NAF previously reported, BioHaven Pharmaceutical Holding Company Ltd. recently completed its 8-week trial of dosing for its drug compound trigriluzole. This is the largest clinical trial for Spinocerebellar Ataxia (SCA) to-date. During the 8-week randomization phase, either the compound Read More…